Analyst resumed coverage on Mirum Pharmaceuticals with a new price target
$MIRM
Biotechnology: Pharmaceutical Preparations
Health Care
Analyst resumed coverage of Mirum Pharmaceuticals with a rating of Overweight and set a new price target of $37.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/17/2024 | $48.00 | Buy | Stifel |
| 12/18/2023 | $60.00 → $58.00 | Buy | H.C. Wainwright |
| 11/20/2023 | $37.00 | Overweight | Analyst |
| 11/13/2023 | $60.00 | Overweight | Morgan Stanley |
| 10/24/2023 | $50.00 | Overweight | Cantor Fitzgerald |
| 10/17/2023 | $62.00 | Outperform | Evercore ISI |
| 9/20/2023 | $70.00 | Mkt Outperform | JMP Securities |
| 9/1/2022 | $38.00 | Buy | Citigroup |
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- 28-week data from the Phase 2b VANTAGE PBC study highlights statistically significant improvements in pruritus and numeric improvements in fatigue, the two most burdensome symptoms of PBC - Seventy percent of patients treated with volixibat experienced a ≥50% reduction in serum bile acids - Volixibat treated patients experienced reductions in IL-31 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today presented new data from its Phase 2b VANTAGE study at the European Association for the Study of the Liver (EASL) meeting in Amsterdam, the Netherlands. The VANTAGE study is evaluating volixibat in patients with cholestatic pruritus caused by primary biliary cholangitis (PBC). "The extended VAN
- First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million - VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026 - LIVMARLI oral tablet formulation FDA approved - Conference call to provide business updates today, May 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the first quarter 2025 and provided a business update. "It's been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline," said Chris Peetz, chief executive officer of Mirum. "We're pleased with the FD
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, May 7, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 549600 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company d
10-Q - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
SCHEDULE 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million - VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026 - LIVMARLI oral tablet formulation FDA approved - Conference call to provide business updates today, May 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the first quarter 2025 and provided a business update. "It's been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline," said Chris Peetz, chief executive officer of Mirum. "We're pleased with the FD
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, May 7, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 549600 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company d
- 2024 net product sales of $336.4 million - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026 - CTEXLI (chenodiol) approved in the US for cerebrotendinous xanthomatosis - Conference call to provide business updates today, February 26 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. "2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue," said Chris Pee
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato
Stifel initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $48.00
H.C. Wainwright reiterated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $58.00 from $60.00 previously
Analyst resumed coverage of Mirum Pharmaceuticals with a rating of Overweight and set a new price target of $37.00
- 2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in second half 2025; topline data expected 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 marked a significant year for Mirum as we accelerated our commercial business and achieved significant development milestones," said Chris
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
Se NodThera Ltd ("NodThera" or the "Company") NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today. With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader. He brings deep expertise across multiple therapy areas, including neuroscience and inflammation, with a strong track reco